Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR) Article

Full Text via DOI: 10.1007/s11239-014-1118-x PMID: 25103613 Web of Science: 000352145200006

Cited authors

  • Sharma, Abhishek; Goel, Sunny; Lavie, Carl J.; Arbab-Zadeh, Armin; Mukherjee, Debabrata; Lazar, Jason


  • Transcatheter aortic valve replacement (TAVR) has been emerged as a promising alternative for the management of patients with severe AS who otherwise are deemed inappropriate candidates for surgery. Post procedural thromboembolic events and risk of bleeding continue to be a significant challenge in managing patients who underwent TAVR. This article systematically reviews the evidence, current guidelines and upcoming studies investigating antithrombotic therapy before, during and after TAVR.

Publication date

  • 2015

International Standard Serial Number (ISSN)

  • 0929-5305

Start page

  • 467

End page

  • 473


  • 39


  • 4